oping to capitalize on consumer outrage, Imprimis Pharmaceuticals (IMMY) plans to sell a cheaper, compounded version of the Restasis dry-eye treatment that is sold by Allergan (AGN) and has been at the center of a widening controversy in recent weeks.

The company plans to sell its version for a fraction of the roughly $500 monthly cost for Restasis, which generated nearly $1.5 billion in sales last year, although may now face generic competition next year after a federal court judge last week invalidated several patents for the medicine.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • ‘Compounding’ or ‘Outsourcing Facility’ … interesting either way. BUT since you brought it up, how much did Turing actually/ever reduce ‘the usuriou$ price’ set by Mr ‘Pharma Bro’ …. if at all? “Promise$, promise$”

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.